-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STP-938 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STP-938 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STP-938 in Follicular Lymphoma Drug Details: STP-938 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EO-2463 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EO-2463 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EO-2463 in Marginal Zone B-cell Lymphoma Drug Details: EO-2463 is...
-
Product Insights
Paraganglioma (Glomus Jugulare Tumor) – Drugs In Development, 2023
Global Markets Direct’s, ‘Paraganglioma (Glomus Jugulare Tumor) - Drugs In Development, 2023’, provides an overview of the Paraganglioma (Glomus Jugulare Tumor) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Paraganglioma (Glomus Jugulare Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Pheochromocytoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pheochromocytoma - Drugs In Development, 2023’, provides an overview of the Pheochromocytoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pheochromocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Adrenal Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Adrenal Gland Cancer - Drugs In Development, 2023’, provides an overview of the Adrenal Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenal Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Drugs In Development, 2023
Global Markets Direct’s, ‘Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drugs In Development, 2023’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Food Allergy – Drugs In Development, 2023
Global Markets Direct’s, ‘Food Allergy - Drugs In Development, 2023’, provides an overview of the Food Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Food Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
B-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroendocrine Tumors – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Tumors - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroendocrine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Cancer - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...